Literature DB >> 9568915

The clinical course of Canavan disease.

E C Traeger1, I Rapin.   

Abstract

Canavan, an autosomal-recessive neurodegenerative disease, is caused by a deficiency of aspartoacylase. Most children are reported to have the infantile form, becoming symptomatic between 3 and 6 months of age, after an unremarkable prenatal and perinatal course. Congenital and juvenile onset forms, although uncommon, do occur. We collected clinical information from the parents of 60 children diagnosed with Canavan disease and reviewed the literature. We conclude that Canavan disease is prenatal in onset with variability in progression. The variable clinical course cannot be explained by genetic heterogeneity but probably depends on environmental factors and/or modifying genes.

Entities:  

Mesh:

Year:  1998        PMID: 9568915     DOI: 10.1016/s0887-8994(97)00185-9

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  19 in total

Review 1.  Molecular water pumps and the aetiology of Canavan disease: a case of the sorcerer's apprentice.

Authors:  M H Baslow
Journal:  J Inherit Metab Dis       Date:  1999-04       Impact factor: 4.982

2.  Redirecting N-acetylaspartate metabolism in the central nervous system normalizes myelination and rescues Canavan disease.

Authors:  Dominic J Gessler; Danning Li; Hongxia Xu; Qin Su; Julio Sanmiguel; Serafettin Tuncer; Constance Moore; Jean King; Reuben Matalon; Guangping Gao
Journal:  JCI Insight       Date:  2017-02-09

3.  Relationship between enzyme properties and disease progression in Canavan disease.

Authors:  Stephen Zano; Yasanandana S Wijayasinghe; Radhika Malik; Joshua Smith; Ronald E Viola
Journal:  J Inherit Metab Dis       Date:  2012-08-01       Impact factor: 4.982

4.  Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.

Authors:  Jiho Sohn; Peter Bannerman; Fuzheng Guo; Travis Burns; Laird Miers; Christopher Croteau; Naveen K Singhal; Jennifer A McDonough; David Pleasure
Journal:  J Neurosci       Date:  2017-01-11       Impact factor: 6.167

5.  N-acetylaspartic acid impairs enzymatic antioxidant defenses and enhances hydrogen peroxide concentration in rat brain.

Authors:  Carolina Didonet Pederzolli; Caroline Paula Mescka; Alessandra Selinger Magnusson; Kátia Bueno Deckmann; Evelise de Souza Streck; Angela Malysz Sgaravatti; Mirian Bonaldi Sgarbi; Angela T S Wyse; Clovis M D Wannmacher; Moacir Wajner; Carlos S Dutra-Filho
Journal:  Metab Brain Dis       Date:  2010-05-01       Impact factor: 3.584

6.  Neuroprotective role of lipoic acid against acute toxicity of N-acetylaspartic acid.

Authors:  Carolina Didonet Pederzolli; Andrea Pereira Rosa; Amanda Szekir de Oliveira; Juliana G Coelho; Débora da Luz Becker; Giovana Reche Dalazen; Tarsila Barros Moraes; Carlos S Dutra-Filho
Journal:  Mol Cell Biochem       Date:  2010-08-05       Impact factor: 3.396

7.  Long-term follow-up after gene therapy for canavan disease.

Authors:  Paola Leone; David Shera; Scott W J McPhee; Jeremy S Francis; Edwin H Kolodny; Larissa T Bilaniuk; Dah-Jyuu Wang; Mitra Assadi; Olga Goldfarb; H Warren Goldman; Andrew Freese; Deborah Young; Matthew J During; R Jude Samulski; Christopher G Janson
Journal:  Sci Transl Med       Date:  2012-12-19       Impact factor: 17.956

8.  Intracerebroventricular administration of N-acetylaspartic acid impairs antioxidant defenses and promotes protein oxidation in cerebral cortex of rats.

Authors:  Carolina Didonet Pederzolli; Francieli Juliana Rockenbach; Fernanda Rech Zanin; Nicoli Taiana Henn; Eline Coan Romagna; Angela M Sgaravatti; Angela T S Wyse; Clóvis M D Wannmacher; Moacir Wajner; Angela de Mattos Dutra; Carlos S Dutra-Filho
Journal:  Metab Brain Dis       Date:  2009-03-18       Impact factor: 3.584

Review 9.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

10.  A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice.

Authors:  Seemin Seher Ahmed; Huapeng Li; Chunyan Cao; Elif M Sikoglu; Andrew R Denninger; Qin Su; Samuel Eaton; Ana A Liso Navarro; Jun Xie; Sylvia Szucs; Hongwei Zhang; Constance Moore; Daniel A Kirschner; Thomas N Seyfried; Terence R Flotte; Reuben Matalon; Guangping Gao
Journal:  Mol Ther       Date:  2013-07-02       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.